Cyramza IV Infusion 10 mg/ml

Cyramza IV Infusion 10 mg/ml Uses, Dosage, Side Effects, Food Interaction and all others data.

Cyramza IV Infusion 10 mg/ml is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells. VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to be heavily involved in cancer progression, making it a highly likely drug target. In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. Cyramza IV Infusion 10 mg/ml is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.

Table Of contents

• Cyramza IV Infusion 10 mg/ml
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Cyramza IV Infusion 10 mg/ml
Availability	Prescription only
Generic	Ramucirumab
Ramucirumab Other Names	Ramucirumab
Related Drugs	Opdivo, methotrexate, Keytruda, capecitabine, pembrolizumab, fluorouracil, doxorubicin, cisplatin, Tagrisso, Avastin
Weight	10 mg/ml
Type	IV Infusion
Formula	C6374H9864N1692O1996S46
Weight	143600.0 Da
Groups	Approved, Investigational
Therapeutic Class
Manufacturer	Healthcare Pharmaceuticals Ltd.
Available Country	Bangladesh
Last Updated:	October 19, 2023 at 6:27 am

Uses

Cyramza IV Infusion 10 mg/ml is an antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply.

For use in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.

Cyramza IV Infusion 10 mg/ml is also used to associated treatment for these conditions: Advanced Gastric Cancer, Advanced gastro-esophageal junction adenocarcinoma, Refractory, metastatic Colorectal cancer, Refractory, metastatic Non small cell lung cancer

How Cyramza IV Infusion 10 mg/ml works

Cyramza IV Infusion 10 mg/ml is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells.

Toxicity

Cyramza IV Infusion 10 mg/ml packaging includes warnings for arterial thromboembolic events, hypertension, infusion-related reactions, gastrointestinal perforation, clinical deterioration in patients with cirrhosis, and reversible posterior leukoencephalopathy syndrome. The most common reactions observed in single-agent-treated patients at a rate of >10% and >2% higher than placebo were hypertension and diarrhea. The most common adverse reactions observed in patients treated with ramucirumab plus paclitaxel at a rate of of >30% and >2% higher than placebo plus paclitaxel were fatigue, neutropenia, diarrhea, and epistaxis.

Food Interaction

No interactions found.

Cyramza IV Infusion 10 mg/ml Drug Interaction

Major: aspirin, heparinUnknown: paclitaxel protein-bound, charcoal, doxorubicin, darbepoetin alfa, fluticasone, diphenhydramine, calcium / vitamin d, doxazosin, sulfamethoxazole / trimethoprim, ubiquinone, prochlorperazine, copper gluconate, ubiquinone, vitamin a topical, bioflavonoids, sotalol, cyanocobalamin, cholecalciferol

Cyramza IV Infusion 10 mg/ml Disease Interaction

Major: bleeding, GI perforationModerate: hypothyroidism, liver dysfunction, hypertension, PRES, proteinuria, thromboembolic disorders

Volume of Distribution

5.5 L

Half Life

15 days

Clearance

0.014 L/hour

Innovators Monograph

You find simplified version here Cyramza IV Infusion 10 mg/ml